**2. Regorafenib**

Regorafenib (BAY 73-4506) is a low-molecular-weight diphenylurea multikinase inhibitor of VEGFR1-3, c-KIT, TIE-2, PDGFR-β, FGFR-1, RET, RAF-1, BRAF, and p38 MAP kinase for oral administration. This agent has been registered for patients with pretreated metastatic colorectal cancers and refractory gastrointestinal stromal tumors (GIST) [1, 2]. Regorafenib is administered at 160 mg daily (q.d.) for 3 weeks of each 4-week cycle (3 week *on*, 1 week *off*), until disease progression or drug intolerance, whichever first.
